Thomas Robeson, MD
Family Medicine · Newport News, VANPI 1982641171
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $25,879 of the $33,777 with a category attached, or 76.6%. It is spread thinly across 60 manufacturers, the largest accounting for just 15.8% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $9,576 and has fallen 69.8% since, to $2,893 in 2025. Among family medicine clinicians in VA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,470 payments — averaging $22.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$5K
- Amgen$4K
- AstraZeneca$4K
- AbbVie$3K
- Novo Nordisk$2K
- GSK$1K
- plus $14K from 54 others
What the payments were for
- Speaking & faculty fees$7,60023%
- Travel & lodging$280%
- Food & beverage$25,87977%
- Education$2691%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$33,777 in reported general payments places this provider in the 95th percentile of 2,553 family medicine providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 128 | $163,829 |
| FarxigaDapagliflozin Propanediol | 136 | $145,093 |
| EliquisApixaban | 118 | $117,036 |
| JardianceEmpagliflozin | 65 | $75,866 |
| TrulicityDulaglutide | 44 | $68,733 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 65 | $62,030 |
| XareltoRivaroxaban | 59 | $52,257 |
| XifaxanRifaximin | 12 | $44,835 |
| Xultophy 100-3.6Insulin Degludec/Liraglutide | 27 | $41,092 |
| MounjaroTirzepatide | 28 | $40,220 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 36 | $39,489 |
| ShingrixVaricella-Zoster Ge/As01b/Pf | 157 | $34,751 |
| ArexvyRsvpref3 Antigen/As01e/Pf | 108 | $33,807 |
| VraylarCariprazine Hcl | 18 | $32,318 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 19 | $26,336 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Xultophy 100-3.6, Rybelsus | $2,084 | $216,096168 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $3,584 | $184,582172 claims |
| GSKTrelegy Ellipta, Shingrix, Arexvy, Breo Ellipta | $1,407 | $148,913349 claims |
| PfizerEliquis | $1,364 | $117,036118 claims |
| Boehringer IngelheimJardiance, Synjardy Xr, Glyxambi | $1,107 | $109,83597 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $5,324 | $108,95372 claims |
| AbbVieVraylar, Viberzi, Synthroid | $2,904 | $58,035105 claims |
| Johnson & JohnsonXarelto | $1,313 | $52,25759 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan | $946 | $44,83512 claims |
| AmgenProlia | $3,694 | $20,69512 claims |
| Astellas Pharma US IncMyrbetriq | $633 | $12,93124 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $125 | $11,55813 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,553 family medicine providers in Virginia.
Other family medicine in Newport News
- Oluwaronke AwosikaFort Gregg Adams$397K
- Monique MatuskowitzNorfolk$110K
- Paul StairsRichmond$105K
- Edwin RobinsonRichmond$83K
- Benjamin PhilpottRocky Mount$64K
- John MolaiyArlington$64K
- Catherine VarneyZion Crossroads$47K
- Jordan TranWinchester$42K
- John ClayColonial Heights$40K
- John ScottGlen Allen$28K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.